CoChat

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer

Open access
Kodama, Michiko, Kodama, Takahiro, Newberg, Justin Y., Katayama, Hiroyuki, Kobayashi, Makoto, Hanash, Samir M., Yoshihara, Kosuke, Wei, Zhubo, Tien, Jean C., Rangel, Roberto, Hashimoto, Kae, Mabuchi, Seiji, Sawada, Kenjiro, Kimura, Tadashi, Copeland, Neal G., Jenkins, Nancy A. · 2017 · Proceedings of the National Academy of Sciences
Cited by 108

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Significance: The poor prognosis of epithelial ovarian cancer (EOC) has not improved for several decades because of drug resistance to current anticancer drugs. Furthermore, few molecularly targeted agents are effective for EOC, likely because EOC has high tumor heterogeneity. Discovering new drug targets and mechanisms involved in the progression of EOC is therefore sorely needed. Our multiple CRISPR and RNAi-based in vivo loss-of-function screens have identified multiple new EOC candidate drug targets, including the druggable oncogene KPNB1, whose inhibition caused multiphased cell cycle arrest and induced apoptosis. Ivermectin, a Food and Drug Administration-approved antiparasitic drug, exerts KPNB1-dependent antitumor effects and synergistically inhibits tumor growth in combination with paclitaxel, and therefore represents a new potential combinatorial therapy for EOC through drug repositioning.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1705441114

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 108

Metadata

Authors
Kodama, M., Kodama, T., Newberg, J. Y., Katayama, H., Kobayashi, M., Hanash, S. M., Yoshihara, K., Wei, Z., Tien, J. C., Rangel, R., Hashimoto, K., Mabuchi, S., Sawada, K., Kimura, T., Copeland, N. G., & Jenkins, N. A.
Venue
Proceedings of the National Academy of Sciences
Published
2017-08-15
Volume
114
Issue
35
Pages
E7301-E7310
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2745505226
Cited by
108
References
10
FWCI
8.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. https://app.cochat.ai/papers/10.1073/pnas.1705441114
The paper
Kodama, M., Kodama, T., Newberg, J. Y., Katayama, H., Kobayashi, M., Hanash, S. M., Yoshihara, K., Wei, Z., Tien, J. C., Rangel, R., Hashimoto, K., Mabuchi, S., Sawada, K., Kimura, T., Copeland, N. G., & Jenkins, N. A. (2017). In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1705441114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.